P/B
1,2
Whitehawk Therapeutics
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
$214.4M
Market Cap • 9/28/2026
2007
(19 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,5
EPS
—
Market Cap
Market Cap
214,4M
EV
24,4M
EV/Revenue
0
EV/EBITDA
-0,3
EV/EBIT
-0,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-40,9%
Total Yield
-40,9%
Dividend Yield 5Y
0%
Payout
0%
Retained Earnings
-392,1M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Net Income 5Y
111,7%
CAGR EPS 5Y
4%
Leverage
N.D./EBITDA
2,2
Debt/Equity
0%
Current Ratio
17,4
Quick Ratio
17,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!